<?xml version="1.0" encoding="UTF-8"?>
<p id="Par2">Several phase III trials on vaccines against SARS-CoV-2 are ongoing and initial results highly promising. A major issue of these phase III trials is to what extent the included study population is representative of the intended (or target) population, i.e. external validity.</p>
